Introduction {#S0001}
============

Thyroid hormones play key roles in energy metabolism, body shape, aging, and glucose and lipid metabolism in humans.[@CIT0001]--[@CIT0005] Accumulated evidence suggested that both underproduction and overproduction of thyroid hormones contributed to the development and the progression of diabetes.[@CIT0006]--[@CIT0010] Ashwini et al reported that mild hypothyroidism improved glucose tolerance and redox in adults.[@CIT0011] Some in vitro and in vivo studies suggested that excessive thyroid hormone might impair the function of islet beta cells, while an appropriate concentration of thyroid hormone could inhibit the apoptosis of islet beta cells and promote the proliferation of islet beta cells.[@CIT0012]--[@CIT0014] Chaker et al pointed out that low and low-normal thyroid function were risk factors for incident diabetes, especially in individuals with prediabetes.[@CIT0015] However, the changes in thyroid hormone levels in euthyroid adults with and without diabetes are still unclear. It is also unknown whether the thyroid hormones change in euthyroid patients with diagnosed diabetes as the disease progresses. This study aimed to investigate the association between the levels of thyroid hormones and diabetes among the euthyroid population.

Methods {#S0002}
=======

Study Design, Settings and Participants {#S0002-S2001}
---------------------------------------

Our study is a retrospective cross-sectional study, collecting health physical examination data from 1 January 2016 to 31 December 2016 in the Physical Examination Center, West China Hospital of Sichuan University.

We included the participants if they: 1) were aged between 20 and 79 years old; 2) had available data of TSH, FT4, FT3, thyroid autoantibodies \[thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb)\], hemoglobin A1c (HbA1c) and fasting blood glucose (FBG); and 3) agreed to the scientific use of their health data and signed the informed consent.

We excluded the patients if their: 1) TPOAb or TGAb were positive; 2) TSH levels were higher than 4.2 mU/L or lower than 0.27 mU/L, out of the normal ranges of reference of the laboratory assay; 3) FT4 or FT3 were out of the normal ranges of reference (12.0\~22.0 pmol/L and 3.6\~7.5 pmol/L, respectively); 4) recorded history included thyroid surgery, diagnosed hypothyroidism, hyperthyroidism or thyroid malignancy; 5) comorbidities included malignancy, coronary artery disease, stroke, chronic obstructive pulmonary disease (COPD) or cirrhosis; and 6) estimated glomerular filtration rate (eGFR) was less than 60 mL/(min·1.73 m^2^).

Grouping {#S0002-S2002}
--------

Diabetes was identified if the patient had previous history of diagnosed diabetes, FBG \>7.0 mmol/L or HbA1c \>6.5%.[@CIT0016] The previous history of diagnosed diabetes was identified by patient self-report with validated records provided by well-trained physicians. Controls without diabetes were identified by 1:1 matching using sex, age (threshold ≤1 yr) and BMI (threshold ≤0.5 kg/m^2^). The patients with diabetes were further divided into two subgroups: patients with newly diagnosed diabetes (NDD) group if they had elevated FBG (\>7.0 mmol/L) or HbA1c (\>6.5%) but were free of self-reported previously diagnosed diabetes, and patients with previously diagnosed diabetes (PDD) group if they had history of diagnosed diabetes before the visit.

Data Source {#S0002-S2003}
-----------

The data were from the Health Physical Examination Center dataset in West China Hospital of Sichuan University. The comorbidities were routinely collected by physician interviewing. Weight (kg), height (cm), waist circumference (WC, cm) and blood pressure were measured. Body mass index (BMI) was calculated using weight (kg) divided by the square of height (m^2^). Thyroid hormones and thyroid autoantibodies were tested using electrochemiluminescence immunoassay (Roche). Other parameters were tested using cobas8000 (Roche) in the clinical laboratory of the hospital, including HbA1c, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and glutamyl transpeptidase (GGT). The eGFR was calculated using the CKD-EPI Creatinine Equation (2009).[@CIT0017]

Variables {#S0002-S2004}
---------

The first binomial outcome of our study was participants with diabetes vs without diabetes, and the second was patients with NDD vs with PDD. The interested factors included levels of TSH, FT4, FT3 and the ratio of FT4/FT3. The other collected variables included age, sex, BMI, diastolic blood pressure (DBP), systolic blood pressure (SBP), WC, HbA1c, FBG, TG, HDL-C, LDL-C, ALT, AST, GGT, eGFR, current smoking, current drinking and whether having hypertension.

Statistical Analyses {#S0002-S2005}
--------------------

The continuous variables, TG, HbA1c, FBG, FT3, HDL-C, ALT, AST, GGT and eGFR, had been tested to be of non-normal distribution by the Kolmogorov--Smirnov test between groups, patients with vs without diabetes and PDD vs. NDD groups. After these variables were transformed more closely to a normal distribution by log transformation, an independent *t*-test was used to investigate the difference of these continuous variables between these groups. The comparison of categorized variables was conducted using the chi-squared test. To compare the levels of TSH, FT4, FT3 and the ratio of FT4/FT3 between the patients with diabetes group and the patients without diabetes group, we used three logistic regression models which were: univariate model (Model 1); multivariate model adjusted for DBP and TG (Model 2); and multivariate model adjusted for Model 2+ALT and eGFR (Model 3). To compare the four thyroid hormone outcomes between the NDD group and the PDD group, four logistic regression models were performed, including: univariate model (Model 1); multivariate model adjusted for age, sex and BMI (Model 2); multivariate model adjusted for Model 2+DBP and TG (Model 3); and multivariate model adjusted for Model 3+ALT and eGFR (Model 4). The adjusted variables of these models were selected if they are available in our data and typically associated with diabetes or thyroid function. Three multivariate models were performed in our study to explore the robustness of the results. The significance level of all analyses above was considered as 0.05, and all analyses were performed using SPSS 24.0.

Results {#S0003}
=======

Baseline Characteristics of the Study Subjects {#S0003-S2001}
----------------------------------------------

We identified 32,557 participants from 170,896 people who underwent physical examinations in 2016 in West China Hospital of Sichuan University. There were 2,271 (7.0%) cases of diabetes, of which 1,187 cases were NDD and 1,084 cases were PDD. The process of study population selection is shown as a flow chart ([Figure 1](#F0001){ref-type="fig"}).Figure 1Screening process of the participants.**Abbreviations:** TSH, thyroid stimulating hormone; FT4, free thyroxine; FT3, free triiodothyronine; TPOAb, thyroid peroxidase antibody; TGAb, thyroglobulin antibody; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.

As shown in [Table 1](#T0001){ref-type="table"}, the average age, BMI and the proportion of male of patients with diabetes were higher. After matching by sex, age and BMI, patients with diabetes presented higher FT4, TG, FPG, HbA1c, ALT, GGT, eGFR, SBP, DBP, WC and FT4/FT3 ratio, and more hypertension, drinking and smoking, but lower TSH, FT3, LDL-C and HDL-C compared to those without diabetes (*P*\<0.01). Compared to the NDD group, patients in the PDD group showed higher FT4, FPG, HDL-C and FT4/FT3 ratio (*P*≤0.01) and a higher portion of females (*P*=0.03), but lower FT3, TG, LDL-C, ALT, AST, GGT, SBP, DBP, BMI and WC, and less alcohol drinking and smoking (*P*\<0.05). There were no statistically significant differences in the levels of TSH, eGFR and HbA1c between NDD and PDD groups (*P*\>0.05).Table 1Baseline Characteristics of ParticipantsParameterControl (n=30,354)DM (n=2271)Matched Control (n=2,243)Matched DM (n=2,243)PNDD (n=1,187)PDD (n=1,084)PAge (yr, SD)43.30 ± 11.0151.66 ± 9.9655.84 ± 9.51\<0.00153.42 ± 9.9453.54 ± 9.850.68Female/case (%)12,212 (40.32)207 (17.44)227 (20.94)0.03422 (18.81)422 (18.81)\>0.99BMI (kg/m^2^, SD)23.58 ± 3.2226.08 ± 3.1824.97 ± 2.91\<0.00125.45 ± 2.9825.47 ± 2.980.79WC (cm, SD)80.21 ± 10.0389.17 ± 8.8886.96 ± 8.69\<0.00186.76 ± 8.4987.97 ± 8.64\<0.001Current smoking/case (%)7,356 (24.29)474 (39.93)352 (32.47)\<0.00125 (1.11)819 (36.51)\<0.001Current drinking/case (%)3,630 (11.99)263 (22.16)175 (16.14)\<0.00112 (5.35)437 (19.48)\<0.001Hypertension/case (%)1,891 (6.24)239 (20.13)318 (29.34)\<0.001333 (14.85)541 (24.12)\<0.001SBP (mmHg, SD)117.19 ± 15.54129.57 ± 17.71127.88 ± 17.240.02125.10 ± 15.77128.58 ± 17.46\<0.001DBP (mmHg, SD)74.00 ± 10.6180.70 ± 11.5176.95 ± 10.46\<0.00177.96 ± 10.2878.88 ± 11.160.004FPG (mmol/L, SD)^a^4.99 ± 0.528.30 ± 2.668.68 ± 3.030.015.15 ± 0.558.49 ± 2.86\<0.001HbA1c (%, SD)^a^5.42 ± 0.357.34 ± 1.387.45 ± 1.590.225.56 ± 0.367.40 ± 1.49\<0.001TG (mmol/L, SD)^a^1.51 ± 1.202.74 ± 2.422.01 ± 1.74\<0.0011.67 ± 1.0732.40 ± 2.16\<0.001LDL-C (mmol/L, SD)2.74 ± 0.732.94 ± 0.812.76 ± 0.79\<0.0012.90 ± 0.722.85 ± 0.81\<0.001HDL-C (mmol/L, SD)^a^1.41 ± 0.401.19 ± 0.341.26 ± 0.37\<0.0011.31 ± 0.341.21 ± 0.35\<0.001TSH (mU/L, SD)2.29 ± 0.872.26 ± 0.892.28 ± 0.880.692.35 ± 0.892.27 ± 0.880.001FT4 (pmol/L, SD)16.90 ± 2.3116.96 ± 2.3017.23 ± 2.410.0116.62 ± 2.2217.09 ± 2.350.001FT3 (pmol/L, SD)^a^5.06 ± 0.865.11 ± 1.024.88 ± 0.88\<0.0015.07 ± 0.655.00 ± 0.97\<0.001FT4/FT3 (SD)3.38 ± 0.483.38 ± 0.563.58 ± 0.55\<0.0013.31 ± 0.483.47 ± 0.560.004ALT (IU/L, SD)^a^27.98 ± 24.9938.24 ± 32.5329.77 ± 18.33\<0.00131.35 ± 23.8034.11 ± 27.06\<0.001AST (IU/L, SD)^a^25.96 ± 15.0030.23 ± 17.5826.39 ± 13.37\<0.00127.85 ± 12.9128.32 ± 15.83\<0.14GGT (IU/L, SD)^a^33.85 ± 42.9569.38 ± 119.1143.92 ± 94.03\<0.00136.33 ± 40.8257.32 ± 109.16\<0.001eGFR (mL/(min·1.73 m^2^), SD)^a^97.03 ± 17.5589.99 ± 14.3389.13 ± 13.580.2286.33 ± 14.2589.64 ± 13.98\<0.001[^2][^3]

The Changes of Thyroid Parameters in Patients with Without Diabetes {#S0003-S2002}
-------------------------------------------------------------------

As shown in [Table 2](#T0002){ref-type="table"}, diabetes was associated with lower TSH and FT3 but higher FT4 and FT4/FT3 ratio in all three models. Compared to patients without diabetes, the ORs per one unit elevation and their 95% CIs of TSH, FT4, FT3 and FT4/FT3 in patients with diabetes were 0.88 (0.82--0.95), 1.11 (1.08--1.14), 0.85 (0.78--0.93) and 2.05 (1.81--2.32) in Model 3, respectively (*P*\<0.001).Table 2The Association Between Diabetes and Thyroid ParametersModel 1Model 2Model 3OR (95% CI)*P*OR (95% CI)*P*OR (95% CI)*P*TSH0.90 (0.84--0.96)0.0010.88 (0.82--0.94)\<0.0010.88 (0.82--0.95)\<0.001FT41.10 (1.07--1.13)\<0.0011.11 (1.08--1.14)\<0.0011.11 (1.08--1.14)\<0.001FT30.89 (0.82--0.97)\<0.0010.86 (0.78--0.93)\<0.0010.85 (0.78--0.93)\<0.001FT4/FT31.84 (1.64--2.07)\<0.0012.02 (1.79--2.28)\<0.0012.05 (1.81--2.32)\<0.001[^4][^5]

The Changes of Thyroid Parameters in Newly and Previously Diagnosed Diabetes {#S0003-S2003}
----------------------------------------------------------------------------

As shown in [Table 3](#T0003){ref-type="table"}, patients in the PDD group presented lower FT3 but higher FT4 and FT4/FT3 ratio in all four models. Compared to the NDD group, the ORs per one unit elevation and their 95% CIs of FT4, FT3 and FT4/FT3 in the PDD group were 1.08 (1.04--1.12; *P*\<0.001), 0.81 (0.71--0.92; *P*=0.002) and 1.76 (1.49--2.08; *P*\<0.001) in Model 4, respectively.Table 3The Difference in Thyroid Parameters Between Newly Diagnosed Diabetes and Previously Diagnosed DiabetesModel 1Model 2Model 3Model 4OR (95% CI)*P*OR (95% CI)*P*OR (95% CI)*P*OR (95% CI)*P*TSH1.02 (0.93--1.12)0.691.00 (0.91--1.10)0.981.01 (0.91--1.11)0.911.01 (0.92--1.12)0.78FT41.05 (1.01--1.09)0.011.08 (1.04--1.12)\<0.0011.08 (1.04--1.12)\<0.0011.08 (1.04--1.12)\<0.001FT30.67 (0.59--0.76)\<0.0010.80 (0.70--0.91)0.0010.79 (0.69--0.90)\<0.0010.81 (0.71--0.92)0.002FT4/FT31.97 (1.68--2.31)\<0.0011.80 (1.52--2.12)\<0.0011.82 (1.54--2.15)\<0.0011.76 (1.49--2.08)\<0.001[^6][^7]

Discussion {#S0004}
==========

Our cross-sectional population-based study suggested that thyroid hormone profiles were associated with diabetes and its duration in euthyroid adults. The FT4/FT3 ratio elevates significantly in patients with diabetes, especially in those with PDD, indicating diabetes with longer duration may be associated with a lower peripheral turnover of thyroxine[@CIT0018],[@CIT0019] and increased chances of developing euthyroid sickness syndrome (ESS).[@CIT0020]--[@CIT0023]

The association between diabetes and thyroid dysfunction including hyperthyroidism and hypothyroidism was well established in previous literature.[@CIT0006],[@CIT0007] Our study is in line with another cross-sectional study of type 2 diabetes in China[@CIT0024] and an observational study of type 1 diabetes in Poland.[@CIT0025] Interestingly, two longitudinal studies from Korea did not prove a statistically significant association between the incidence of diabetes and the suppressed TSH level, but the individual-level changes of TSH.[@CIT0026],[@CIT0027] However, a cohort study from Rotterdam suggested that higher TSH levels and lower FT4 levels within the reference range of thyroid function were associated with a higher risk of diabetes,[@CIT0015] while another cohort study in the Netherlands showed no association between plasma TSH levels and incident T2DM.[@CIT0028] Cross-sectional studies in Korea and Peru suggested increased FT3 and FT3/FT4 ratio are associated with metabolic syndrome and insulin resistance.[@CIT0029]--[@CIT0031] The difference in these results may be explained by the study population. All participants with thyroid autoimmunity were excluded from our analysis. They are found in over 10% of the population and likely to develop early-stage thyroid dysfunction, which may elevate or reduce the TSH levels. None of the previous studies excluded the impact of thyroid autoimmunity, which may slightly affect the results.[@CIT0015],[@CIT0026]-[@CIT0028] To be noted, two cohort studies from the Netherlands included Caucasian adults with higher cardiovascular risks than our study population,[@CIT0015],[@CIT0028] while the Korean study was more in line with us.[@CIT0026],[@CIT0027] It suggested this association could be ethnicity-based and needed more validation in different populations.

The suppressed TSH level in the PDD group may be partially explained by the increased risk of ESS and metformin therapy in this population.[@CIT0009],[@CIT0032],[@CIT0033] Changes in thyroid hormone metabolism due to altered type 1, 2 and 3 deiodinase may underlie the observation since these enzymes had shown altered activity in models of disease or inflammation,[@CIT0034],[@CIT0035] meaning the FT3 level declined and the FT4/FT3 ratio evaluated as the duration grew, indicating the typical change of ESS[@CIT0036] along with the deterioration of diabetes. It suggests periodic screening of thyroid hormones in euthyroid patients with diabetes may not be necessary since ESS is an adaptive change of peripheral turnover of thyroid hormones.

Our study has some strengths. Firstly, the study enrolled a large population of confirmed euthyroid adults, which may better reflect the pathophysiological changes of thyroid hormones in patients with diabetes. Secondly, controls were selected by 1:1 matching and three multivariate models in the study showed consistent results, which suggested the robustness of our results.

However, our study has some limitations. Firstly, this is a cross-sectional study, which cannot conclude the causation between thyroid hormone profiles and diabetic development. Secondly, the study population was recruited from the health examination participants, possibly different from the community-based population. Thirdly, we could not access the detailed duration of diabetes or the undergoing treatment of the patients, which might be unadjusted biases in the study, but we could conclude the duration of PDD was longer than that of NDD, since all patients in NDD were diagnosed in 2016, while all patients in PDD were diagnosed before 2016. Fourthly, we did not differentiate type 1 and type 2 diabetes because of the limitation of the patient information. Nonetheless, type 2 diabetes was likely to be demonstrative according to the epidemiology of diabetes in China. Finally, we did not evaluate the levels of rT3, which may help confirm the conversive changes of the thyroid hormones but is unavailable in the data source.

Conclusion {#S0005}
==========

Our study found an elevated FT4/FT3 ratio in euthyroid patients with newly or previously diagnosed diabetes, especially in the latter, suggesting alterations in thyroid hormone turnover in these patients.
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